Janney Montgomery Scott LLC Invests $402,000 in Haemonetics Co. (NYSE:HAE)

Janney Montgomery Scott LLC purchased a new position in shares of Haemonetics Co. (NYSE:HAE) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 5,147 shares of the medical instruments supplier’s stock, valued at approximately $402,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Nisa Investment Advisors LLC grew its holdings in shares of Haemonetics by 124.2% during the third quarter. Nisa Investment Advisors LLC now owns 1,141 shares of the medical instruments supplier’s stock worth $92,000 after purchasing an additional 632 shares during the last quarter. iSAM Funds UK Ltd bought a new position in shares of Haemonetics in the third quarter valued at about $204,000. CWC Advisors LLC. acquired a new position in Haemonetics during the 3rd quarter worth about $231,000. Versor Investments LP grew its holdings in Haemonetics by 9.1% during the 3rd quarter. Versor Investments LP now owns 3,600 shares of the medical instruments supplier’s stock worth $289,000 after acquiring an additional 300 shares during the last quarter. Finally, Verdence Capital Advisors LLC acquired a new stake in Haemonetics in the 3rd quarter valued at about $302,000. 99.67% of the stock is owned by institutional investors and hedge funds.

Haemonetics Trading Up 2.0 %

NYSE HAE opened at $60.51 on Tuesday. Haemonetics Co. has a 12 month low of $58.80 and a 12 month high of $97.97. The stock has a 50-day simple moving average of $76.38 and a 200 day simple moving average of $78.22. The company has a current ratio of 3.97, a quick ratio of 2.09 and a debt-to-equity ratio of 1.35. The company has a market capitalization of $3.04 billion, a PE ratio of 23.82, a P/E/G ratio of 0.98 and a beta of 0.39.

Haemonetics (NYSE:HAE) last announced its quarterly earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 EPS for the quarter, missing analysts’ consensus estimates of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. Research analysts forecast that Haemonetics Co. will post 4.59 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on HAE. Bank of America lowered shares of Haemonetics from a “neutral” rating to an “underperform” rating and reduced their target price for the stock from $95.00 to $68.00 in a research report on Friday. Raymond James reaffirmed a “strong-buy” rating and set a $115.00 price objective (down previously from $120.00) on shares of Haemonetics in a report on Friday. Needham & Company LLC lowered their target price on Haemonetics from $112.00 to $108.00 and set a “buy” rating for the company in a research note on Friday. StockNews.com raised Haemonetics from a “hold” rating to a “buy” rating in a research note on Friday. Finally, JMP Securities lowered their price objective on Haemonetics from $125.00 to $100.00 and set a “market outperform” rating for the company in a research report on Friday. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $101.67.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.